智通财经网·2025-08-11 10:36Core Insights - Fosun Pharma has signed a licensing agreement with Expedition Therapeutics for the development, production, and commercialization rights of the small molecule oral DPP-1 inhibitor XH-S004 globally, excluding mainland China and Hong Kong and Macau [1][2] - Fosun Pharma will retain the rights for XH-S004 in mainland China and Hong Kong and Macau [1] - Expedition will pay up to $120 million in non-refundable upfront payments and milestone payments based on development and annual net sales achievements, potentially totaling up to $525 million [1] Company Overview - XH-S004 is a small molecule oral DPP-1 inhibitor developed by Fosun Pharma, which reduces inflammation by inhibiting DPP-1 and its activated neutrophil serine proteases, thereby blocking the vicious cycle of infection and airway structural damage [2] - Currently, XH-S004 is in Phase II clinical trials for the treatment of non-cystic fibrosis bronchiectasis and in Phase Ib clinical trials for chronic obstructive pulmonary disease (COPD) in mainland China [2] - There are no approved small molecule oral inhibitors with the same molecular mechanism globally as of now [2]